Park Ha Biological Technology Faces Securities Class Action Lawsuit
A securities class action lawsuit has been filed against Park Ha Biological Technology Co., Ltd. concerning BYAH stock. Investors who purchased or acquired the company's shares within a specific period may be eligible for recovery.
San Diego, Calif. – Robbins LLP has notified investors of a securities class action lawsuit filed against Park Ha Biological Technology Co., Ltd. (NASDAQ: BYAH).
The lawsuit encompasses all persons and entities who purchased or otherwise acquired Park Ha Biological Technology securities between December 27, 2024, and a specified date. The allegations suggest the company made misleading statements and omitted material information to investors, impacting the stock's value.
Robbins LLP is seeking individuals with information or those who have incurred losses due to the decline in BYAH stock value to contact the firm. Further details regarding the legal proceedings and potential recovery options are available.
Park Ha Biological Technology is a biotechnology company listed on the NASDAQ. The company focuses on research and development within the biotechnology sector. Additional context on the company's specific market or competitive landscape was not immediately available.